In accordance with our recent study highlighting the association of MUC16 with metastasis in PC, ch5E6 treated tumors had a significantly decreased number of metastases (P = 0.00029) in the liver (Supplementary Fig. 6d) Taken together, both subcutaneous and orthotopic xenograft models of PC and NSCLC demonstrated the therapeutic efficacy of ch5E6 as a monotherapy regimen. This evidence concerns the gene MUC16 and non-small cell lung carcinoma.